Ponatinib: Promises and Challenges

Elias Jabbour, MD, leads a discussion about dosing challenges and strategies with ponatinib and other tyrosine kinase inhibitors.

[Jacelyn]

I realize that Ponatinib was stopped for very good reasons. However, in my experience, in a very short time, it had taken my CML down to very low levels. Too bad it could not have worked better -- I think from what I experienced that it would have been a fast acting drug in controlling CML.